The design and discovery of novel amide CCR5 antagonists
摘要:
The synthesis of a range of novel amine-containing structures and their primary potency as inhibitors of HIV-1 fusion via blocking of the CCR5 receptor is described. The development of the medicinal chemistry strategy and SAR's which led to the identification of the piperidine amide compounds 33 and 36 as excellent leads for further evaluation is described, along with key physicochemical data which highlighted their lead potential. (C) 2009 Elsevier Ltd. All rights reserved.
The design and discovery of novel amide CCR5 antagonists
摘要:
The synthesis of a range of novel amine-containing structures and their primary potency as inhibitors of HIV-1 fusion via blocking of the CCR5 receptor is described. The development of the medicinal chemistry strategy and SAR's which led to the identification of the piperidine amide compounds 33 and 36 as excellent leads for further evaluation is described, along with key physicochemical data which highlighted their lead potential. (C) 2009 Elsevier Ltd. All rights reserved.
The present invention provides compounds of formula (I) wherein R
1
, R
2
, R
3
, R
4
, R
5
, m and n are as defined hereinabove. The compounds of the present invention are modulators, especially antagonists, of the activity of chemokine CCR5 receptors. Modulators of the CCR5 receptor may be useful in the treatment of various inflammatory diseases and conditions, and in the treatment of infection by HIV and genetically related retroviruses.
The design and discovery of novel amide CCR5 antagonists
作者:David C. Pryde、Martin Corless、David R. Fenwick、Helen J. Mason、Blanda C. Stammen、Peter T. Stephenson、David Ellis、David Bachelor、David Gordon、Christopher G. Barber、Anthony Wood、Donald S. Middleton、David C. Blakemore、Gemma C. Parsons、Rachel Eastwood、Michelle Y. Platts、Keith Statham、Kerry A. Paradowski、Catherine Burt、Wolfgang Klute
DOI:10.1016/j.bmcl.2009.01.012
日期:2009.2
The synthesis of a range of novel amine-containing structures and their primary potency as inhibitors of HIV-1 fusion via blocking of the CCR5 receptor is described. The development of the medicinal chemistry strategy and SAR's which led to the identification of the piperidine amide compounds 33 and 36 as excellent leads for further evaluation is described, along with key physicochemical data which highlighted their lead potential. (C) 2009 Elsevier Ltd. All rights reserved.